EANM guideline on quality risk management for radiopharmaceuticals

Nic Gillings; Olaug Hjelstuen; Martin Behe; Clemens Decristoforo; Philip H Elsinga; Valentina Ferrari; Oliver C Kiss; Petra Kolenc; Jacek Koziorowski; Peter Laverman; Thomas L Mindt; Meltem Ocak; Marianne Patt; Sergio Todde; Almut Walte

doi:10.1007/s00259-022-05738-4

EANM guideline on quality risk management for radiopharmaceuticals

Nic Gillings, Olaug Hjelstuen, Martin Behe, Clemens Decristoforo, Philip H Elsinga, Valentina Ferrari, Oliver C Kiss, Petra Kolenc, Jacek Koziorowski, Peter Laverman, Thomas L Mindt, Meltem Ocak, Marianne Patt, Sergio Todde, Almut Walte

Afdeling for Klinisk Fysiologi og Nuklearmedicin

Abstract

This document is intended as a supplement to the EANM "Guidelines on current Good Radiopharmacy Practice (cGRPP)" issued by the Radiopharmacy Committee of the EANM (Gillings et al. in EJNMMI Radiopharm Chem. 6:8, 2021). The aim of the EANM Radiopharmacy Committee is to provide a document that describes how to manage risks associated with small-scale "in-house" preparation of radiopharmaceuticals, not intended for commercial purposes or distribution.

Originalsprog	Engelsk
Tidsskrift	European Journal of Nuclear Medicine and Molecular Imaging
Vol/bind	49
Udgave nummer	10
Sider (fra-til)	3353-3364
Antal sider	12
ISSN	1619-7070
DOI	https://doi.org/10.1007/s00259-022-05738-4
Status	Udgivet - aug. 2022

Adgang til dokumentet

10.1007/s00259-022-05738-4

Andre filer og links

Link to publication in Scopus

Citationsformater

Gillings, N., Hjelstuen, O., Behe, M., Decristoforo, C., Elsinga, P. H., Ferrari, V., Kiss, O. C., Kolenc, P., Koziorowski, J., Laverman, P., Mindt, T. L., Ocak, M., Patt, M., Todde, S., & Walte, A. (2022). EANM guideline on quality risk management for radiopharmaceuticals. European Journal of Nuclear Medicine and Molecular Imaging, 49(10), 3353-3364. https://doi.org/10.1007/s00259-022-05738-4

Gillings, N, Hjelstuen, O, Behe, M, Decristoforo, C, Elsinga, PH, Ferrari, V, Kiss, OC, Kolenc, P, Koziorowski, J, Laverman, P, Mindt, TL, Ocak, M, Patt, M, Todde, S & Walte, A 2022, 'EANM guideline on quality risk management for radiopharmaceuticals', European Journal of Nuclear Medicine and Molecular Imaging, bind 49, nr. 10, s. 3353-3364. https://doi.org/10.1007/s00259-022-05738-4

@article{a5bf4f33c9e643d0b7b7076336d4ae98,

title = "EANM guideline on quality risk management for radiopharmaceuticals",

abstract = "This document is intended as a supplement to the EANM {"}Guidelines on current Good Radiopharmacy Practice (cGRPP){"} issued by the Radiopharmacy Committee of the EANM (Gillings et al. in EJNMMI Radiopharm Chem. 6:8, 2021). The aim of the EANM Radiopharmacy Committee is to provide a document that describes how to manage risks associated with small-scale {"}in-house{"} preparation of radiopharmaceuticals, not intended for commercial purposes or distribution.",

keywords = "Humans, Nuclear Medicine, Radiopharmaceuticals/adverse effects, Risk Management",

author = "Nic Gillings and Olaug Hjelstuen and Martin Behe and Clemens Decristoforo and Elsinga, {Philip H} and Valentina Ferrari and Kiss, {Oliver C} and Petra Kolenc and Jacek Koziorowski and Peter Laverman and Mindt, {Thomas L} and Meltem Ocak and Marianne Patt and Sergio Todde and Almut Walte",

note = "{\textcopyright} 2022. The Author(s).",

year = "2022",

month = aug,

doi = "10.1007/s00259-022-05738-4",

language = "English",

volume = "49",

pages = "3353--3364",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer",

number = "10",

}

TY - JOUR

T1 - EANM guideline on quality risk management for radiopharmaceuticals

AU - Gillings, Nic

AU - Hjelstuen, Olaug

AU - Behe, Martin

AU - Decristoforo, Clemens

AU - Elsinga, Philip H

AU - Ferrari, Valentina

AU - Kiss, Oliver C

AU - Kolenc, Petra

AU - Koziorowski, Jacek

AU - Laverman, Peter

AU - Mindt, Thomas L

AU - Ocak, Meltem

AU - Patt, Marianne

AU - Todde, Sergio

AU - Walte, Almut

PY - 2022/8

Y1 - 2022/8

N2 - This document is intended as a supplement to the EANM "Guidelines on current Good Radiopharmacy Practice (cGRPP)" issued by the Radiopharmacy Committee of the EANM (Gillings et al. in EJNMMI Radiopharm Chem. 6:8, 2021). The aim of the EANM Radiopharmacy Committee is to provide a document that describes how to manage risks associated with small-scale "in-house" preparation of radiopharmaceuticals, not intended for commercial purposes or distribution.

AB - This document is intended as a supplement to the EANM "Guidelines on current Good Radiopharmacy Practice (cGRPP)" issued by the Radiopharmacy Committee of the EANM (Gillings et al. in EJNMMI Radiopharm Chem. 6:8, 2021). The aim of the EANM Radiopharmacy Committee is to provide a document that describes how to manage risks associated with small-scale "in-house" preparation of radiopharmaceuticals, not intended for commercial purposes or distribution.

KW - Humans

KW - Nuclear Medicine

KW - Radiopharmaceuticals/adverse effects

KW - Risk Management

UR - http://www.scopus.com/inward/record.url?scp=85127647209&partnerID=8YFLogxK

U2 - 10.1007/s00259-022-05738-4

DO - 10.1007/s00259-022-05738-4

M3 - Journal article

C2 - 35385986

SN - 1619-7070

VL - 49

SP - 3353

EP - 3364

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - 10

ER -

EANM guideline on quality risk management for radiopharmaceuticals

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater